PAB 14.3% 0.8¢ patrys limited

Ann: PAT-DX1 Conjugated to Nanoparticles, Targets Tumors, page-17

  1. 2,140 Posts.
    lightbulb Created with Sketch. 103
    This is certainly great news for the medical field ------

    Patrys has selected a high-performing variant of Deoxymab 3E10, PAT-DX1 as the lead candidate from the program and is progressing PAT-DX1, and its nanoparticle-conjugated form PAT-DX1-NP into pre-clinical cancer models. Patrys believes that PAT-DX1 may have application across a wide range of malignancies such as gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers.

    If this is not fantastic I don’t know what is.
 
watchlist Created with Sketch. Add PAB (ASX) to my watchlist
(20min delay)
Last
0.8¢
Change
0.001(14.3%)
Mkt cap ! $14.40M
Open High Low Value Volume
0.7¢ 0.8¢ 0.7¢ $26.93K 3.669M

Buyers (Bids)

No. Vol. Price($)
1 98812 0.7¢
 

Sellers (Offers)

Price($) Vol. No.
0.8¢ 4509656 3
View Market Depth
Last trade - 14.25pm 01/07/2024 (20 minute delay) ?
PAB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.